Coherus BioSciences (CHRS) Tops Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.27 +3.25%
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $14.31 million versus the consensus estimate of $14.41 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Securitize Corp (SECZ) PT Raised to $12 at StoneX on 'Innovation Exemption'
- KLX Energy Services $125M rights offering set to expire Sept. 23
- French 10-year Yield Climbs 11Bps To 4.56%, Highest Since 2008 - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
